Loading...
Market
How much will Asceneuron raise in its next major funding round by the end of 2025?
3
Resolution / Starting Odds
Less than $50M • 25%
$50M - $100M • 25%
$100M - $150M • 25%
More than $150M • 25%
Press releases from Asceneuron, financial news outlets, and investment announcements
Story
Asceneuron Raises $100M in Series C for Alzheimer's Drug Development
Jul 16, 2024, 08:01 AM
Swiss biotech company Asceneuron announced it has raised $100 million in an oversubscribed Series C financing round. The funding, led by Novo Holdings, will be used to advance the clinical development of its Alzheimer's disease drug, targeting Tau protein aggregation. Investors include EQT Life Sciences, SofinnovaVC, and other notable backers. The raised capital will support the progression of Asceneuron's lead asset, ASN51, into Phase 2 clinical trials. The drug is being developed as an oral therapy. Professor Scheltens has joined the board to further bolster the company's expertise.
View original story
Similar markets
Less than $20 million • 25%
$20 million to $50 million • 25%
$51 million to $100 million • 25%
More than $100 million • 25%
No additional funding • 25%
Up to $10 million • 25%
$10 million to $50 million • 25%
Over $50 million • 25%
Less than €10M • 25%
Between €10M and €20M • 25%
Between €20M and €30M • 25%
More than €30M • 25%
Less than $100 million • 25%
$100 million to $199 million • 25%
$200 million to $299 million • 25%
$300 million or more • 25%
Less than $10 million • 25%
$10 million to $20 million • 25%
$20 million to $50 million • 25%
More than $50 million • 25%
Less than £50 million • 25%
£50 million to £100 million • 25%
£100 million to £150 million • 25%
More than £150 million • 25%
Less than $100 million • 25%
$100 million - $199 million • 25%
$200 million - $299 million • 25%
$300 million or more • 25%
Above $300 million • 33%
Between $200 million and $300 million • 34%
Below $200 million • 33%
Less than $50M • 25%
$50M to $100M • 25%
$100M to $150M • 25%
More than $150M • 25%
Less than $150M • 25%
$150M - $200M • 25%
$200M - $250M • 25%
More than $250M • 25%